Form 4: Casdin Partners Increases Stake in Standard BioTools Inc. with $545,000 Purchase

Casdin Partners Master Fund, L.P. reports purchasing 250,000 shares of Standard BioTools Inc. at a weighted average price of $2.187 per share, increasing their total holdings.

Summary

• On August 27, 2024, Casdin Partners Master Fund, L.P. acquired 250,000 shares of Standard BioTools Inc. common stock at a weighted average price of $2.187 per share.
• The purchase price ranged from $2.1746 to $2.1953 per share.
• Following the transaction, Casdin Partners Master Fund, L.P. directly owns 2,781,432 shares and indirectly owns a total of 54,025,821 shares.
• The reporting persons include Casdin Partners Master Fund, L.P., Eli Casdin, Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund II GP, LLC, Casdin Private Growth Equity Fund, L.P., Casdin Amplify Fund, LP, and CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC.
• Eli Casdin is a director of Standard BioTools Inc. and may be deemed a director by deputization for the reporting persons.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a purchase of shares by a major shareholder, which could be interpreted as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• Increased investment by a major shareholder, Casdin Partners, could signal confidence in Standard BioTools Inc.'s future prospects.

Management Comments

• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing reflects ongoing investment activity in the life sciences tools and diagnostics sector, where Standard BioTools operates.

Stakeholder Impact

• The increased stake by Casdin Partners could be viewed positively by shareholders.

Key Dates